Draft. Pending scientific and legal review. Not medical advice.
What is pharmacogenomics?
Pharmacogenomics studies the link between genotype and drug response. It may help anticipate toxicity, lack of efficacy or the need to adjust dose according to guidelines such as CPIC or DPWG. It does not replace medical prescribing. Always consult a healthcare professional before changing treatment.
Definition
Pharmacogenomics analyses genetic variants that influence absorption, transport, metabolism, elimination and drug targets. The aim is to provide information that, together with clinical judgement, may guide medicine choice and dose.
It is not a disease diagnosis. It supports prescribing.
What is usually measured
ADME genes are often studied, along with phase I and II hepatic enzymes (for example CYP2D6, CYP2C19, CYP2C9, CYP3A4, UGT, NAT2, TPMT), transporters (SLCO1B1, ABCB1) and receptors or targets (such as VKORC1). PharmGKB summarises evidence for many gene-drug pairs; CPIC and DPWG publish clinical guidelines when evidence allows.
What not to do with the result
Do not change or stop a medicine without consulting the prescribing professional. Age, weight, liver and kidney function, interactions and habits also modify response.
To see how this line appears in the Xenomium catalogue, read the pharmacogenomics area page.
